ClinicalTrialsFinder
RecruitingNot ApplicableNCT04534127

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

Sponsor

Alpha Tau Medical LTD.

Enrollment

56 participants

Start Date

Dec 22, 2020

Study Type

INTERVENTIONAL

Conditions

Skin CancerMucosal Neoplasm of Oral CavitySoft Tissue Neoplasm

Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

Eligibility

Min Age: 18 Years

Inclusion Criteria15

  • Subjects with histopathological confirmation of primary or secondary malignant cutaneous neoplastic lesions, or oral cavity mucosal tumors, or superficial soft tissue sarcoma. Confirmation obtained within 6 months of planned treatment.
  • Subjects with a tumor size ≤ 7 centimeters in the longest diameter.
  • Targetable lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds
  • Brachytherapy indication validated by a multidisciplinary team
  • Patients who have either failed first-line treatment, or are medically unfit for standard of care (surgery, external-beam radiation therapy or chemotherapy), or refuse standard of care.
  • Measurable disease according to RECIST v1.1.
  • Subjects over 18 years old.
  • Subjects' ECOG Performance Status Scale is \< 2.
  • Subjects' life expectancy is more than 6 months.
  • Platelet count ≥100,000/mm3.
  • WBC ≥ 3500/μl, granulocyte ≥ 1500/μl
  • AST and ALT ≤ 2.5 X ULN
  • International normalized ratio of prothrombin time ≤1.8.
  • Creatinine ≤1.9 mg/dL. Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy.
  • Subjects are willing to sign an informed consent form.

Exclusion Criteria11

  • Subject has a tumor of Keratoacanthoma histology.
  • Known hypersensitivity to any of the components of the treatment.
  • Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.
  • Any medical or psychiatric illness which in the opinion of the investigator would compromise the patient's ability to tolerate this treatment or interfere with the study endpoints.
  • Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids
  • Patient requires treatment which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT
  • Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
  • Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
  • High probability of protocol non-compliance (in opinion of investigator).
  • Subjects not willing to sign an informed consent.
  • Women who are pregnant or breastfeeding.

Interventions

DEVICERadiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.

Locations(1)

Sharett institute, Hadassah Medical Center - Ein-Kerem

Jerusalem, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04534127

Related Trials

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

NCT069260753 locations

Prospective Registry of Histotripsy for Soft Tissue Tumors

NCT074700081 location

The Florida ASCENT Study

NCT070422431 location

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

NCT043540641 location

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

NCT074227791 location